400 µg of MBX 2109 once-weekly by subcutaneous injection

Drug identity checked against registry records

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With HypoparathyroidismNCT06531941MBX BiosciencesPhase 2Active not recruiting2028-05Estimated

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.